Abstract:Primary erythromelalgia (PE ORPHA90026) is a rare autosomal dominant neuropathy characterized by the combination of recurrent burning pain, warmth and redness of the extremities. The incidence rate of PE ranges from 0.36 to 1.1 per 100,000 persons. Gender ratio differs according to different studies and no evidence showed a gender preference. Clinical onset of PE is often in the first decade of life. Burning pain is the most predominant symptom and is usually caused and precipitated by warmth and physical activities. Reported cases of PE contain both inherited and sporadic forms. Genetic etiology of PE is mutations on SCN9A, the encoding gene of a voltage-gated sodium channel subtype Nav1.7. Diagnosis of PE is made upon clinical manifestations and screening for mutations on SCN9A. Exclusion of several other treatable diseases/secondary erythromelalgia is also necessary because of the lack of biomarkers specifically for PE. Differential diagnoses can include Fabry disease, cellulites, Raynaud phenomenon, vasculitis and so on. Diagnostic methods often involve complete blood count, imaging studies and thermograph. Treatment for PE is unsatisfactory and highly individualized. Frequently used pain relieving drugs involve sodium channel blockers such as lidocaine, carbamazepine and mexiletine. Novel drugs such as PF-05089771 and TV-45070 could be promising in ameliorating pain symptoms due to their Nav1.7 selectivity. Patients' symptoms often worsen over time and many patients develop ulcerations and gangrenes caused by excessive exposure to low temperature in order to relieve pain. This review mainly focuses on PE and the causative gene SCN9A - its mutations and their effects on Nav1.7 channels' electrophysiological properties. We propose a genotype-channelopathy-phenotype correlation network underlying PE etiology which could provide guidance for future therapeutics.

Paroxysmal extreme pain disorder associated with a mutation in SCN9A gene – Case report and own experiences

A Novel SCN9A Gene Variant Identified in a Chinese Girl with Paroxysmal Extreme Pain Disorder (PEPD): a Rare Case Report.

Two Novel<i>SCN9A</i>Gene Heterozygous Mutations May Cause Partial Deletion of Pain Perception

SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes

Genetic, Electrophysiological, and Pathological Studies on Patients with SCN9A-related Pain Disorders.

Primary erythromelalgia caused by SCN9A gene mutation: A case report and literature review

Genetic pain loss disorders

A Gain-of-Function Mutation in TRPA1 Causes Familial Episodic Pain Syndrome

Genetic Analysis of SCN11A, SCN10A, and SCN9A in Familial Episodic Pain Syndrome (FEPS) in Japan and Proposal of Clinical Diagnostic Criteria

Novel Missense Variant in the TMEM151A Gene Causing Paroxysmal Kinesigenic Dyskinesia: a Case Report with Literature Review

Pain perception is altered by a nucleotide polymorphism in SCN9A

Primary Erythromelalgia: A Review

Familial Episodic Pain Syndromes

Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations

Gain-of-Function mutations in SCN11A cause familial episodic pain

GENES CONTRIBUTING TO PAIN SENSITIVITY IN THE NORMAL POPULATION: AN EXOME SEQUENCING STUDY

Congenital Insensitivity to Pain: A Case Study of a Rare Genetic Disorder

Pathological Changes of the Sural Nerve in Patients with Familial Episodic Pain Syndrome

Case Report: Mutant SCN9A Susceptible to Charcot Neuroarthropathy in a Patient with Congenital Insensitivity to Pain.

A Systematic Review of Congenital Insensitivity to Pain, a Rare Disease

Congenital Insensitivity to Pain with Multiple Fractures: A Case Report and Literature Review